J Korean Assoc Oral Maxillofac Surg.  2017 Oct;43(5):305-311. 10.5125/jkaoms.2017.43.5.305.

Count of platelet and mean platelet volume score: serologic prognostic factor in patients with oral squamous cell carcinoma

• Park JW
• Kim CH
• Ha YC
• Kim MY
• Park SM

• KMID: 2393595
• DOI: http://doi.org/10.5125/jkaoms.2017.43.5.305

Abstract

OBJECTIVES
TNM staging, especially for lymph node metastasis, is the scoring system most widely used among prognostic factors for cancer survival. Several biomarkers have been studied as serologic markers, but their specificity is low and clinical applications are difficult. This study aimed to establish a scoring system for patients with oral squamous cell carcinoma (OSCC) using platelet (PLT) and mean platelet volume (MPV) levels measured postoperatively and to evaluate their significance as prognostic factors.
MATERIALS AND METHODS
We studied 40 patients admitted to the Department of Oral and Maxillofacial Surgery of Dankook University Hospital who were diagnosed with primary OSCC histopathologically between May 2006 and May 2012. Clinical pathological information obtained from the medical records of each patient included age, sex, height, weight, tumor location, degree of differentiation, tumor diameter, lymph node metastasis, TNM stage, and other test values including white blood cell, MPV, PLT, C-reactive protein (CRP), and albumin obtained through a test conducted within 7 days before surgery. Count of platelet (COP)-MPV Score: Patients with both PLT and MPV values below the cut-off values were defined as score 0 (group A). Patients with at least one of the two higher than the cut-off value were defined as score 1 (group B).
RESULTS
Univariate analyses showed N-metastasis, COP-MPV (A vs B), PLT, platelet-lymphocyte ratio, and CRP were statistically significant prognostic factors. A multivariate Cox proportional hazards model showed N-metastasis (hazard ratio [HR] 6.227, P=0.016) and COP-MPV (A vs B) (HR 18.992, P=0.013) were independent prognostic factors with a significant effect on survival.
CONCLUSION
COP-MPV score is a simple and cost-effective test method and is considered a more effective prognostic factor than other considered factors in predicting the prognosis of OSCC patients.

Keyword

Oral squamous cell carcinoma; Prognostic factor; Count of platelet; Mean platelet volume

MeSH Terms

Biomarkers
Blood Platelets*
C-Reactive Protein
Carcinoma, Squamous Cell*
Epithelial Cells*
Humans
Leukocytes
Lymph Nodes
Mean Platelet Volume*
Medical Records
Methods
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Proportional Hazards Models
Sensitivity and Specificity
Surgery, Oral
Tumor Burden
Biomarkers
C-Reactive Protein

Figure

• 

  Fig. 1 Kaplan-Meier curves of overall survival between count of platelet and mean platelet volume (COP-MPV) scores 0 and 1.

• 

  Fig. 2 Kaplan-Meier curves of overall survival between N-metastasis yes and no.

Reference

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11–30. PMID: 23335087.

2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–E386. PMID: 25220842.

3. Johnson N. Tobacco use and oral cancer: a global perspective. J Dent Educ. 2001; 65:328–339. PMID: 11336118.

4. Reibel J. Tobacco and oral diseases. Update on the evidence, with recommendations. Med Princ Pract. 2003; 12(Suppl 1):22–32. PMID: 12707498.

5. Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biörklund A, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer. 1998; 82:1367–1375. PMID: 9529030.

6. Llewellyn CD, Johnson NW, Warnakulasuriya KA. Risk factors for squamous cell carcinoma of the oral cavity in young people--a comprehensive literature review. Oral Oncol. 2001; 37:401–418. PMID: 11377229.

7. Singh B, Bhaya M, Zimbler M, Stern J, Roland JT, Rosenfeld RM, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998; 20:1–7. PMID: 9464945.

8. Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg. 2002; 128:268–274. PMID: 11886342.

9. Lydiatt DD, Robbins KT, Byers RM, Wolf PF. Treatment of stage I and II oral tongue cancer. Head Neck. 1993; 15:308–312. PMID: 8360052.

10. Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope. 2005; 115:629–639. PMID: 15805872.

11. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001; 345:1890–1900. PMID: 11756581.

12. Woolgar JA, Rogers S, West CR, Errington RD, Brown JS, Vaughan ED. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol. 1999; 35:257–265. PMID: 10621845.

13. Yotsukura S, Mamitsuka H. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint. Crit Rev Oncol Hematol. 2015; 93:103–115. PMID: 25459666.

14. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002; 3:27–34. PMID: 11908507.

15. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002; 3:425–430. PMID: 12142172.

16. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11:123–134. PMID: 21258396.

17. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001; 22:1561–1571. PMID: 11492985.

18. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005; 25:709–713. PMID: 15868900.

19. Kurt M, Onal IK, Sayilir AY, Beyazit Y, Oztas E, Kekilli M, et al. The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology. 2012; 59:1580–1582. PMID: 22683976.

20. Karaman K, Bostanci EB, Aksoy E, Kurt M, Celep B, Ulas M, et al. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas. Eur J Intern Med. 2011; 22:e95–e98. PMID: 22075321.

21. Kılınçalp S, Ekiz F, Başar O, Ayte MR, Coban S, Yılmaz B, et al. Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets. 2014; 25:592–594. PMID: 23537073.

22. Connolly GC, Phipps RP, Francis CW. Platelets and cancer-associated thrombosis. Semin Oncol. 2014; 41:302–310. PMID: 25023346.

23. Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014; 133(Suppl 2):S149–S157. PMID: 24862136.

24. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost. 2004; 92:185–190. PMID: 15213860.

25. Li L, Li P, Yang YQ, Zhang H, Ai P, Wang F, et al. sCD40L, sP-selectin and sICAM-1 plasma levels in nasopharyngeal carcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009; 40:513–516. PMID: 19627017.

26. Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012; 15:265–273. PMID: 22402885.

27. Azab B, Torbey E, Singh J, Akerman M, Khoueiry G, McGinn JT, et al. Mean platelet volume/platelet count ratio as a predictor of long-term mortality after non-ST-elevation myocardial infarction. Platelets. 2011; 22:557–566. PMID: 21714700.

28. Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2011; 31:1215–1218. PMID: 21330610.

29. Cho SY, Yang JJ, You E, Kim BH, Shim J, Lee HJ, et al. Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets. 2013; 24:375–377. PMID: 22835043.

30. Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B. Platelet activation in patients with advanced gastric cancer. Neoplasma. 2010; 57:145–150. PMID: 20099978.

31. Mutlu H, Artis TA, Erden A, Akca Z. Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin Appl Thromb Hemost. 2013; 19:331–333. PMID: 22345488.

32. Goldstein DP, Irish JC. Head and neck squamous cell carcinoma in the young patient. Curr Opin Otolaryngol Head Neck Surg. 2005; 13:207–211. PMID: 16012243.

33. Sarkaria JN, Harari PM. Oral tongue cancer in young adults less than 40 years of age: rationale for aggressive therapy. Head Neck. 1994; 16:107–111. PMID: 8021128.

34. Veness MJ, Morgan GJ, Sathiyaseelan Y, Gebski V. Anterior tongue cancer: age is not a predictor of outcome and should not alter treatment. ANZ J Surg. 2003; 73:899–904. PMID: 14616566.

35. Popovtzer A, Shpitzer T, Bahar G, Marshak G, Ulanovski D, Feinmesser R. Squamous cell carcinoma of the oral tongue in young patients. Laryngoscope. 2004; 114:915–917. PMID: 15126756.

36. Patel SC, Carpenter WR, Tyree S, Couch ME, Weissler M, Hackman T, et al. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol. 2011; 29:1488–1494. PMID: 21383286.

37. Marocchio LS, Lima J, Sperandio FF, Corrêa L, de Sousa SO. Oral squamous cell carcinoma: an analysis of 1,564 cases showing advances in early detection. J Oral Sci. 2010; 52:267–273. PMID: 20587952.

38. Chow CW, Tabrizi SN, Tiedemann K, Waters KD. Squamous cell carcinomas in children and young adults: a new wave of a very rare tumor? J Pediatr Surg. 2007; 42:2035–2039. PMID: 18082703.

39. Zhang WB, Wang Y, Mao C, Guo CB, Yu GY, Peng X. Cervical metastasis of maxillary squamous cell carcinoma. Int J Oral Maxillofac Surg. 2015; 44:285–291. PMID: 25467737.

40. Zhang F, Chen Z, Wang P, Hu X, Gao Y, He J. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumour Biol. 2016; 37:9323–9331. PMID: 26779631.

41. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009; 45:912–914. PMID: 19502100.

42. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol. 2006; 12:3746–3750. PMID: 16773693.

43. Park HC, Kim MY, Kim CH. C-reactive protein/albumin ratio as prognostic score in oral squamous cell carcinoma. J Korean Assoc Oral Maxillofac Surg. 2016; 42:243–250. PMID: 27847731.